Biosplice logo_final RGB 300 dpi_white background.png
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program
March 08, 2024 13:36 ET | Biosplice Therapeutics, Inc.
Biosplice announced today that its collaboration with The Roskamp Institute has been awarded funding by the US Department of Defense.
Global Neurological Biomarkers Market
Global Neurological Biomarkers Market Analysis Report 2024-2030 - CAGR of 12.8% - Increased Funding For R&D in Biomarkers to Boost Development of New Drugs
January 24, 2024 05:40 ET | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Neurological Biomarkers Market Size, Share & Trends Analysis Report by Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism),...
Moleac logo.png
Moleac’s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury
December 04, 2023 22:41 ET | Moleac Pte Ltd
Promising results from the SAMURAI study show NeuroAiDTMII significantly improves post-concussion symptoms, QoL and mood post-mild traumatic brain injury.
Global Neurological Biomarkers Market
Neurological Biomarkers Research Report 2023: A Global $18.75 Billion Market by 2030 with Pipeline Analysis of Alzheimer's, Parkinson's, Multiple Sclerosis, & Autism Spectrum Disorder
November 14, 2023 05:28 ET | Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), By Type,...
Logo.png
Traumatic Brain Injury Market to Register Sustainable Growth by 2032, Evaluates DelveInsight | Leading Companies in the Market - Life Molecular Imaging, Merz, Vasopharm, Pinteon, Omniscient Neurotechnology
October 18, 2023 13:00 ET | DelveInsight Business Research LLP
New York, USA, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Traumatic Brain Injury Market to Register Sustainable Growth by 2032, Evaluates DelveInsight | Leading Companies in the Market - Life Molecular...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues
October 04, 2023 07:05 ET | ZyVersa Therapeutics
Brain inflammation from traumatic injury releases proinflammatory cytokines that activate inflammasomes in the heart leading to damaging inflammation.
Aviv-Clinic Logo.png
Aviv Clinics Highlights New Literature Review Sharing the Efficacy of Hyperbaric Oxygen Therapy for Traumatic Brain Injury Patients
August 01, 2023 13:24 ET | Aviv Clinics
ORLANDO, Fla., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Aviv Clinics, one of the most advanced brain clinics in the world, shares the results of a new comprehensive literature review that shows hyperbaric...
The Dan Lewis Foundation for Brain Regeneration Research Announces First Annual DLF Prize to Be Awarded Spring 2023 DENVER, Feb. 23, 2023 (GLOBE NEWSWIRE) -- The Dan Lewis Foundation for Brain Regeneration Research (the DLF) happily announces the 2023 DLF Prize. This $15,000 prize will be awarded to an early...
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces New Publication in Translational Research Showing IC 100 Reduces Inflammasome Activation in Mouse Model for Alzheimer’s Disease Following Traumatic Brain Injury
February 23, 2023 09:20 ET | ZyVersa Therapeutics
Data published in Translational Research indicate that pyroptotic release of cytokines and ASC Specks from traumatic brain injury (TBI) induces a heightened inflammasome response in Alzheimer’s...
Algernon Logo 1.png
Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor
February 21, 2023 07:00 ET | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...